

Neptune Technologies & Bioresources Inc.
Form 6-K
April 14, 2010

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, DC 20549

FORM 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

For the month of: April 2010

Commission File Number: 001-33526

NEPTUNE TECHNOLOGIES & BIORESOURCES INC.

(Name of Registrant)

225 Promende du Centropolis

Suite 200

Laval, Québec

Canada H7T 0B3

(Address of Principal Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F []

Form 40-F [X]

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): []

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): []

Edgar Filing: Neptune Technologies & Bioresources Inc. - Form 6-K

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934:

Yes []

No [X]

If Yes is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): N/A

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

NEPTUNE TECHNOLOGIES & BIORESOURCES INC.

Date: April 14, 2010

| | |
|--------|---------------------------------------|
| By: | /s/ Henri Harland |
| Name: | Henri Harland |
| Title: | President and Chief Executive Officer |

EXHIBIT INDEX

Exhibit Description of Exhibit

99.1 Acasti Pharma Inc. to showcase at the Cambridge Healthtech Institute and the BioPharmaceutical Strategy Series
